Conflombardia – Europa
Territori d’Europa
Tutti gli articoli
www.ema.europa.eu Brussels, 14 July 2026 Dear Ms Jerkovic, dear honourable members, thank you for the invitation today and for this opportunity to report on EMA’s activities. Many of you know that it’s my last annual exchange with this committee, because my mandate will end in April, and I...
www.ema.europa.eu Brussels, 14 July 2026 Check against delivery Dear Ms Jerkovic, dear honourable members, thank you for the invitation today and for this opportunity to report on EMA’s activities. Many of you know that it’s my last annual exchange with this committee, because my mandate...
www.ema.europa.eu PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata Desogestrel- and etonogestrel-containing medicines: risk of meningioma and new measures to minimise this risk PRAC agreed on a...
www.ema.europa.eu PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata Desogestrel- and etonogestrel-containing medicines: risk of meningioma and new measures to minimise this risk PRAC agreed on a...
www.ema.europa.eu EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases, as they...
www.ema.europa.eu EMA’s initiatives in this area will be discussed through a dedicated women’s health workshop on 28-29 September. The workshop, broadcast live, will take stock of current activities across the EU, including from EMA, national regulators and other organisations. It will...